Analysis of Thyroid Cancer Incidence Trends in Altai Krai Focusing on the Impact of Papillary Microcarcinomas on Morbidity Structure
- Authors: Zakharova I.M.1,2, Lazarev A.F.1, Petrova V.D.1, Ganov D.I.1, Terekhova S.A.1, Trukhacheva N.V.1, Antonova J.A.1, Semeryanova E.K.1
-
Affiliations:
- Altai State Medical University
- Altai Regional Oncology Dispensary
- Issue: Vol 30, No 1 (2025)
- Pages: 31-40
- Section: Original Study Articles
- URL: https://ogarev-online.ru/1028-9984/article/view/313546
- DOI: https://doi.org/10.17816/onco643155
- EDN: https://elibrary.ru/XPSWYQ
- ID: 313546
Cite item
Abstract
BACKGROUND: In recent years, the incidence of thyroid cancer has been increasing, primarily due to the rising detection of papillary microcarcinomas (T1a). However, the mortality rates have not declined. This study is devoted to evaluate trends in thyroid cancer incidence in Altai Krai, with a particular focus on the T1a subcategory.
AIM: The work aimed to study the trends of thyroid cancer incidence in Altai Krai in 2014–2023, with a focus on tumors at the papillary microcarcinoma stage (T1a), including their recurrence rates.
METHODS: Data from the regional cancer registry were used. Incidence rates, stage distribution, histological structure, and recurrence rates were assesed. The data were than compared to those from across Russia, along with the international data on active observation.
RESULTS: The incidence rate in the region was 3–4 times higher than the average rate in Russia. Stage T1 accounted for 66.4% of cases, with T1a representing 36.1%. The recurrence rate of papillary microcarcinomas remained below 4%, with a declining trend reaching 0.35% in 2023.
CONCLUSION: The high proportion of early-stage tumors and the low recurrence rate of papillary microcarcinomas highlight the potential for incorporating active surveillance strategies into Russian clinical practice.
Full Text
##article.viewOnOriginalSite##About the authors
Irina M. Zakharova
Altai State Medical University; Altai Regional Oncology Dispensary
Author for correspondence.
Email: zaxarova270494@mail.ru
ORCID iD: 0000-0003-2225-619X
SPIN-code: 2550-6903
Russian Federation, Barnaul; Barnaul
Alexander F. Lazarev
Altai State Medical University
Email: lazarev@akzs.ru
ORCID iD: 0000-0003-1080-5294
SPIN-code: 1161-8387
MD, Dr. Sci. (Medicine), Professor
Russian Federation, BarnaulValentina D. Petrova
Altai State Medical University
Email: valent_04@mail.ru
ORCID iD: 0000-0001-7169-9646
SPIN-code: 2941-6649
MD, Dr. Sci. (Medicine)
Russian Federation, BarnaulDmitry I. Ganov
Altai State Medical University
Email: ganovdmit@yandex.ru
ORCID iD: 0000-0002-7118-1668
SPIN-code: 2100-7576
MD, Cand. Sci. (Medicine), Associate Professor
Russian Federation, BarnaulSvetlana A. Terekhova
Altai State Medical University
Email: asmu.oncology@mail.ru
ORCID iD: 0009-0001-4594-4529
SPIN-code: 7564-1647
MD, Cand. Sci. (Medicine)
Russian Federation, BarnaulNina V. Trukhacheva
Altai State Medical University
Email: tn10@mail.ru
ORCID iD: 0000-0002-7894-4779
SPIN-code: 3515-5231
Cand. Sci. (Pedagogy), Associate Professor
Russian Federation, BarnaulJulia A. Antonova
Altai State Medical University
Email: antonovaj_18@mail.ru
ORCID iD: 0009-0004-8885-2730
SPIN-code: 7946-2299
Russian Federation, Barnaul
Elizaveta K. Semeryanova
Altai State Medical University
Email: liiikaaaaz@mail.ru
SPIN-code: 1937-2194
Russian Federation, Barnaul
References
- Ivanov VL, Gorsky AI, Polkin VV, et al. Dynamics of thyroid cancer incidence in the population of Russia: main risk factors. Radiation and Risk. 2022;31(4):6–20. doi: 10.21870/0131-3878-2022-31-4-6-20
- Miyauchi A, Kudo T, Ito Y, et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery. 2018;163(1):48–52. doi: 10.1016/j.surg.2017.03.028
- Tuttle RM, Fagin JA, Minkowitz G, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143(10):1015–1020. doi: 10.1001/jamaoto.2017.1442
- Oh HS, Ha J, Kim HI, et al. Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. Thyroid. 2018;28(12):1587–1594. doi: 10.1089/thy.2018.0263
- Sugitani I, Ito Y, Takeuchi D, et al. Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. Thyroid. 2021;31(2):183–192. doi: 10.1089/thy.2020.0330
- Afanasyeva ZA, Vasilevskaya SM, Druzhkova NB, et al. Experience in the diagnosis and treatment of thyroid microcarcinoma at the Republican clinical oncological dispensary named after professor M.Z. Segal of the ministry of health of the Republic of Tatarstan. Voprosy onkologii. 2023;69(3S):186–187. (In Russ.) EDN: KVPWOV
- Stilidi IS, Zaridze DG, Maksimovich DM, Dzitiev DM. The decrease in the incidence of malignant tumors as a consequence of the epidemic of COVID-19. Public Health. 2022;2(1):5–14. doi: 10.21045/2782-1676-2021-2-1-5-14
- Minkin AU, Vereshchagin MYu, Lutkov DV, et al. Analysis of the incidence of thyroid cancer in the Arkhangelsk Region. Russian Journal of Oncology. 2019;24(12):60–62. (In Russ.) EDN: VNPBTC
- Tkachev VV, Dunaev AV, Girdaladze TM, Senchukova MA. The state of the oncological care to patients with thyroid cancer in Orenburg Region and Russian Federation. Oncology Bulletin of the Volga region. 2018;(2):41–48. (In Russ.) EDN: YMBNNJ
- Molinaro E, Campopiano MC, Pieruzzi L, et al. Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. The Journal of Clinical Endocrinology & Metabolism. 2020;105(3):e172–e180. doi: 10.1210/clinem/dgz113
- Saravana-Bawan B, Bajwa A, Paterson J, McMullen T. Active surveillance of low-risk papillary thyroid cancer: A meta-analysis. Surgery. 2020;167(1):46–55. doi: 10.1016/j.surg.2019.03.040
- Lee EK, Moon JH, Hwangbo Y, et al. Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea. Thyroid. 2022;32(11):1328–1336. doi: 10.1089/thy.2021.0614
- Solodky VA, Fomin DK, Galushko DA, Asmaryan AG. Papillary thyroid microcarcinoma: distinct form or cancer growth stage? Endocrine Surgery. 2020;14(4):19–25. doi: 10.14341/serg12696
- Kuznetsov NS, Skibitskaya MV, Vainshtok AP, Vashchenko EA. Investigation of the possibility of predicting recurrence in patients with papillary thyroid cancer. Innovative technologies in endocrinology. 2024. (In Russ.) doi: 10.14341/Cong21-24.05.24-263
- Ito Y, Miyauchi A, Kihara M, et al. Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation. Thyroid. 2014;24(1):27–34. doi: 10.1089/thy.2013.0367
Supplementary files
